FDA Recalls 112,000 Bottles of Beta-Blocker Medication: What Wholesale Distributors Need to Know

On January 13, 2025, the FDA announced a voluntary Class II recall of 112,000 bottles of Metoprolol Succinate Extended-Release Tablets USP, 25 mg, manufactured by Alembic Pharmaceuticals Inc. and distributed by Strides Pharma Inc. Wholesale drug distributors holding inventory or having distributed this lot must execute quarantine and customer notification procedures under 21 CFR Part 7.

Regulatory Context

FDA drug recall procedures follow a tiered classification system under 21 CFR Part 7, Subpart C. Class II recalls indicate a product that "may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote." The classification triggers specific pharmaceutical recall management obligations for entities in the distribution chain.

Under the DSCSA (Drug Supply Chain Security Act), wholesale drug distributors must maintain the ability to quarantine suspect or illegitimate products and notify trading partners within 24 hours of determination. While this recall originates from the manufacturer, not a DSCSA-triggered investigation, the operational requirements for distributors remain consistent: identify affected inventory, prevent further distribution, and execute reverse logistics for return or destruction.

Recall Details

Product: Metoprolol Succinate Extended-Release Tablets USP, 25 mg

NDC: 70528-0020-01

Lot Number: MA230086

Quantity: 112,000 bottles (500 tablets per bottle)

Expiration Date: February 2027

Reason: Failed dissolution testing during stability studies

Risk Assessment: Patients may not receive the full therapeutic dose, potentially resulting in uncontrolled blood pressure or worsening heart failure symptoms

The recall was initiated on January 8, 2025. Strides Pharma is notifying distributors and customers by mail and arranging for product return. The FDA posted the recall to its Enforcement Reports on January 13, 2025.

Distributor Action Requirements

Wholesale drug distributors must execute the following pharmaceutical drug recall procedures:

1. Inventory identification — Cross-reference NDC 70528-0020-01, Lot MA230086 against current stock. Check all storage locations, including quarantine areas where prior suspect product may be held.

1. Immediate quarantine — Segregate identified inventory to prevent dispensing or distribution. Apply physical quarantine labels or tags. Update inventory management systems to block lot from picking and shipping workflows.

1. Customer notification — Identify all customers who received product from Lot MA230086. Under drug distribution compliance protocols, notification must occur within 24 hours of recall identification. Include lot number, NDC, expiration date, and instructions for return.

1. Reverse logistics execution — Coordinate with Strides Pharma for return authorization and shipping instructions. Maintain chain of custody documentation for returned product. If destruction is required instead of return, follow 21 CFR 1317.75 for controlled substance destruction procedures (metoprolol is not a controlled substance, but documentation standards for reverse logistics pharmaceuticals still apply).

1. Reconciliation and reporting — Document total quantity identified, quarantined, and returned. Retain records for the later of three years or one year after the product's expiration date, per 21 CFR 205.50(g) for pedigree and transaction history retention.

Wholesale drug distributor requirements under state pharmacy board rules may impose additional notification or reporting obligations. California, for example, requires wholesalers to report recalls to the California State Board of Pharmacy within 72 hours under Business and Professions Code Section 4059.5.

What ColdChainCheck Data Shows

As of January 2025, ColdChainCheck tracks 73 entities with at least one FDA recall on record out of 1,275 total wholesale drug distributors and 3PLs in the directory. This represents 5.7% of tracked entities. The presence of a recall does not indicate current non-compliance — many entities with historical recalls maintain excellent compliance scores based on current licensure and accreditation status.

Strides Pharma Inc., the distributor named in this recall, is not currently listed in the ColdChainCheck directory. This recall will be added to our enforcement tracking once the entity is profiled. Alembic Pharmaceuticals Inc., the manufacturer, falls outside our scope (we track wholesale distributors and 3PLs, not manufacturers).

The average compliance score across all entities is 51/100, placing the industry median in the "Fair" tier. Only 63 entities hold NABP accreditation (formerly VAWD), representing less than 5% of the directory. This concentration means most distributors rely on state licensure and FDA registration as their primary compliance signals — making recall response procedures a direct test of operational compliance infrastructure.

Compliance Actions for QA Managers

If your organization sources beta-blockers or works with entities that do:

• Check trading partner status — Use the ColdChainCheck directory to verify FDA registration and state licensure for all distributors in your metoprolol supply chain. Entities with active FDA registration and no enforcement history demonstrate stronger recall response capability.

• Review recall notification timelines — If you received notification from Strides Pharma or a downstream distributor, document the notification date. DSCSA compliance requires notification within 24 hours of recall determination. Delays indicate gaps in trading partner systems. Review the DSCSA compliance checklist for complete notification requirements.

• Audit reverse logistics protocols — This recall requires product return to Strides Pharma. Entities with documented reverse logistics procedures and temperature-controlled return shipping are more likely to maintain product integrity during the recall process. ColdChainCheck's compliance score does not yet factor reverse logistics capability, but state licensure (25 points of the score) requires written recall procedures.

• Monitor for secondary recalls — Metoprolol is distributed under multiple brand names and NDCs. The FDA Enforcement Reports page updates weekly. Subscribe to FDA email alerts for beta-blocker recalls or use ColdChainCheck's regulatory guides for ongoing DSCSA enforcement updates.

Entities with multiple state licenses (scored higher in ColdChainCheck's "State Licensure Coverage" category) face more complex multi-jurisdiction recall requirements. A distributor licensed in 40 states must verify recall notification rules in each jurisdiction — some states require board notification within 72 hours, others have no explicit requirement.

Disclaimer: This article is for informational purposes only and does not constitute legal or regulatory advice. Wholesale drug distributors should consult with qualified legal counsel and verify all recall requirements with the FDA and applicable state pharmacy boards.